Title: A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Journal: Journal of medicinal chemistry 20180125
Title: Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Journal: Blood cancer journal 20151001
Title: Association between polymorphisms of the IKZF3 gene and systemic lupus erythematosus in a Chinese Han population.
Journal: PloS one 20140101
Title: Chad C Bjorklund, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020 Apr;34(4):1197-1201.
Title: Erin W Meermeier, et al. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy. Blood Cancer Discov. 2021 Jul;2(4):354-369.